This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Valeant Pharmaceuticals International Inc (VRX)

NYSE: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) -863.67M -116.02M 0.00 -208.19M
Operating Gains/Losses 69.37M 8.46M 5.78M 78.39M
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -261.38M -219.43M -164.58M 25.19M
(Increase) Decrease in Inventories -122.70M -80.30M -11.52M 7.46M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables -76.55M -29.07M -8.98M -76.10M
(Decrease) Increase In Other Current Liabilities 0.00 20.70M 54.68M 17.01M
(Increase) Decrease In Other Working Capital 0.00 0.00 -3.63M -2.82M
Other Non-Cash Items 625.16M 314.40M 410.17M 213.38M
Net Cash From Continuing Operations 1.04B 656.58M 676.47M 263.19M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 1.04B 656.58M 676.47M 263.19M
Sale of Property, Plant & Equipment 0.00 92.00M 0.00 15.05M
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -184.96M -181.13M -385.95M -16.82M
Acquisitions -5.25B -3.49B -2.46B 224.45M
Purchases of Short-Term Investments 0.00 -7.20M -81.09M 0.00
Other Cash from Investing Activities 41.09M -8.87M 0.00 -1.70M
Cash Provided by Financing Activities
Net Cash From Investing Activities -5.38B -2.97B -2.84B 228.94M
Issuance of Debt 8.47B 6.04B 5.39B 992.40M
Cash Used for Financing Activities
Issuance of Capital Stock 10.02M 23.03M 41.74M 58.42M
Repayment of Long-Term Debt -6.40B -2.57B -2.62B -796.38M
Repurchase of Capital Stock -55.63M -280.72M -639.24M -60.13M
Payment of Cash Dividends 0.00 0.00 0.00 -356.29M
Other Financing Charges, Net 2.01B -155.61M -225.02M -51.31M
Net Cash From Financing Activities 4.03B 3.06B 1.95B -213.28M
Effect of Exchange Rate Changes -5.07M 3.76M -10.29M 959.00K
Net Change in Cash & Cash Equivalents -315.75M 751.98M -230.16M 279.81M
VRX News

VRX Valeant Pharmaceuticals International Inc

Analysts Ratings for VRX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 8 8 8 8
Moderate Buy 1 0 1 1
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

Brokerage Partners

VRX Chatter

Select the service that is right for you!

Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs